Skip to main content
. 2020 May 14;21(10):3460. doi: 10.3390/ijms21103460

Figure 1.

Figure 1

The relationship of actomyosin contractility and acute myeloid leukemia (AML) cell growth. (A) The localization of non-muscle myosin II (NMII) A or B (green) and their spatial relationship with phallodin (magenta) in AML cell line HL-60. (B) Immunofluorescence images of the phosphorylation level of the myosin regulatory light chain (pMRLC) expression between normal CD34+ cells and HL-60 cells. (C) Quantification of the expression of pMRLC in AML cell lines (THP-1 and U-937) (CD34+: n = 67; HL-60: n = 44; THP-1: n = 39; U-937: n = 71). Data are presented as median ± min/max. (D) Viable HL-60 cells counted after treatment with the indicated dose of blebbistatin (BB) in 24 h (n = 3). Data are represented as mean ± SEM. (E) Representative images of the colonies of HL-60 cells in methylcellulose-based medium with blebbistatin treatment. (F) The results of blebbistatin (50 µM) induced cell number changes between normal 32Dcl3 myeloid cells and HL-60 cells in a time-dependent manner (n = 6). Data are represented as mean ± SEM. (G) Quantification of the cell number changes of various leukemic cell lines upon 50 µM blebbistatin treatment (n = 6). Data are represented as mean ± SEM. Scale bars: 5 µm (A), 50 µm (B). * p < 0.05, ** p < 0.01, *** p < 0.001.